

CONSORT-EHEALTH (V 1.6.1) - Submission/Publication Form

The CONSORT-EHEALTH checklist is intended for authors of randomized trials evaluating web-based and Internet-based applications/interventions, including mobile interventions, electronic games (incl multiplayer games), social media, certain telehealth applications, and other interactive and/or networked electronic applications. Some of the items (e.g. all subitems under item 5 - description of the intervention) may also be applicable for other study designs.

The goal of the CONSORT EHEALTH checklist and guideline is to be
a) a guide for reporting for authors of RCTs,
b) to form a basis for appraisal of an ehealth trial (in terms of validity)

CONSORT-EHEALTH items/subitems are MANDATORY reporting items for studies published in the Journal of Medical Internet Research and other journals / scientific societies endorsing the checklist.

Items numbered 1., 2., 3., 4a., 4b etc are original CONSORT or CONSORT-NPT (non-pharmacologic treatment) items.

Items with Roman numerals (i., ii, iii, iv etc.) are CONSORT-EHEALTH extensions/clarifications.

As the CONSORT-EHEALTH checklist is still considered in a formative stage, we would ask that you also RATE ON A SCALE OF 1-5 how important/useful you feel each item is FOR THE PURPOSE OF THE CHECKLIST and reporting guideline (optional).

Mandatory reporting items are marked with a red *.

In the textboxes, either copy & paste the relevant sections from your manuscript into this form - please include any quotes from your manuscript in QUOTATION MARKS, or answer directly by providing additional information not in the manuscript, or elaborating on why the item was not relevant for this study.

YOUR ANSWERS WILL BE PUBLISHED AS A SUPPLEMENTARY FILE TO YOUR PUBLICATION IN JMIR AND ARE CONSIDERED PART OF YOUR PUBLICATION (IF ACCEPTED).

Please fill in these questions diligently. Information will not be copyedited, so please use proper spelling and grammar, use correct capitalization, and avoid abbreviations.

DO NOT FORGET TO SAVE AS PDF _AND_ CLICK THE SUBMIT BUTTON SO YOUR ANSWERS ARE IN OUR DATABASE !!!

You're editing your response. Sharing this URL allows others to also edit your response.

[FILL OUT A NEW RESPONSE](#)

Eysenbach G, CONSORT-EHEALTH Group

CONSORT-EHEALTH: Improving and Standardizing Evaluation Reports of Web-based and Mobile Health Interventions

J Med Internet Res 2011;13(4):e126

URL: <http://www.jmir.org/2011/4/e126/>

doi: 10.2196/jmir.1923

PMID: 22209829

**sshagrawi@gmail.com** (not shared) [Switch account](#)

Resubmit to save

*** Required****Your name ***

First Last

Salah Alshagrawi

Primary Affiliation (short), City, Country *

University of Toronto, Toronto, Canada

Saudi Electronic University

Your e-mail address *[abc@gmail.com](#)

sshagrawi@gmail.com

Title of your manuscript *

Provide the (draft) title of your manuscript.

A randomized controlled trial to determine the efficacy of mHealth behavioral change

You're editing your response. Sharing this URL allows others to also edit your response.

FILL OUT A NEW RESPONSE

Name of your App/Software/Intervention *

If there is a short and a long/alternate name, write the short name first and add the long name in brackets.

mHealth

Evaluated Version (if any)

e.g. "V1", "Release 2017-03-01", "Version 2.0.27913"

Your answer

Language(s) *

What language is the intervention/app in? If multiple languages are available, separate by comma (e.g. "English, French")

English

URL of your Intervention Website or App

e.g. a direct link to the mobile app on app in appstore (itunes, Google Play), or URL of the website. If the intervention is a DVD or hardware, you can also link to an Amazon page.

Your answer

URL of an image/screenshot (optional)

Your answer

You're editing your response. Sharing this URL allows others to also edit your response.

FILL OUT A NEW RESPONSE

Accessibility *

Can an enduser access the intervention presently?

- ☒ access is free and open
- ☐ access only for special usergroups, not open
- ☐ access is open to everyone, but requires payment/subscription/in-app purchases
- ☐ app/intervention no longer accessible
- ☐ Other:

Primary Medical Indication/Disease/Condition *

e.g. "Stress", "Diabetes", or define the target group in brackets after the condition, e.g. "Autism (Parents of children with)", "Alzheimers (Informal Caregivers of)"

physical inactivity

Primary Outcomes measured in trial *

comma-separated list of primary outcomes reported in the trial

physical activity (steps)

Secondary/other outcomes

Are there any other outcomes the intervention is expected to affect?

Secondary/other outcomes
: Body Mass Index

You're editing your response. Sharing this URL allows others to also edit your response.

FILL OUT A NEW RESPONSE

Recommended "Dose" *

What do the instructions for users say on how often the app should be used?

- ☐ Approximately Daily
- ☒ Approximately Weekly
- ☐ Approximately Monthly
- ☐ Approximately Yearly
- ☐ "as needed"
- ☐ Other:

Approx. Percentage of Users (starters) still using the app as recommended after 3 months *

- ☒ unknown / not evaluated
- ☐ 0-10%
- ☐ 11-20%
- ☐ 21-30%
- ☐ 31-40%
- ☐ 41-50%
- ☐ 51-60%
- ☐ 61-70%
- ☐ 71-80%
- ☐ 81-90%
- ☐ 91-100%

You're editing your response. Sharing this URL allows others to also edit your response.

[FILL OUT A NEW RESPONSE](#)

Overall, was the app/intervention effective? *

- ☒ yes: all primary outcomes were significantly better in intervention group vs control
- ☐ partly: SOME primary outcomes were significantly better in intervention group vs control
- ☐ no statistically significant difference between control and intervention
- ☐ potentially harmful: control was significantly better than intervention in one or more outcomes
- ☐ inconclusive: more research is needed
- ☐ Other:

Article Preparation Status/Stage *

At which stage in your article preparation are you currently (at the time you fill in this form)

- ☐ not submitted yet - in early draft status
- ☐ not submitted yet - in late draft status, just before submission
- ☐ submitted to a journal but not reviewed yet
- ☐ submitted to a journal and after receiving initial reviewer comments
- ☒ submitted to a journal and accepted, but not published yet
- ☐ published
- ☐ Other:

You're editing your response. Sharing this URL allows others to also edit your response.

[FILL OUT A NEW RESPONSE](#)

Journal *

If you already know where you will submit this paper (or if it is already submitted), please provide the journal name (if it is not JMIR, provide the journal name under "other")

- ☐ not submitted yet / unclear where I will submit this
- ☒ Journal of Medical Internet Research (JMIR)
- ☐ JMIR mHealth and UHealth
- ☐ JMIR Serious Games
- ☐ JMIR Mental Health
- ☐ JMIR Public Health
- ☐ JMIR Formative Research
- ☐ Other JMIR sister journal
- ☐ Other:

Is this a full powered effectiveness trial or a pilot/feasibility trial? *

- ☐ Pilot/feasibility
- ☒ Fully powered

Manuscript tracking number *

If this is a JMIR submission, please provide the manuscript tracking number under "other" (The ms tracking number can be found in the submission acknowledgement email, or when you login as author in JMIR. If the paper is already published in JMIR, then the ms tracking number is the four-digit number at the end of the DOI, to be found at the bottom of each published article in JMIR)

- ☐ no ms number (yet) / not (yet) submitted to / published in JMIR

You're editing your response. Sharing this URL allows others to also edit your response.

FILL OUT A NEW RESPONSE

TITLE AND ABSTRACT

1a) TITLE: Identification as a randomized trial in the title

1a) Does your paper address CONSORT item 1a? *

I.e does the title contain the phrase "Randomized Controlled Trial"? (if not, explain the reason under "other")

☒ yes

☐ Other:

1a-i) Identify the mode of delivery in the title

Identify the mode of delivery. Preferably use "web-based" and/or "mobile" and/or "electronic game" in the title. Avoid ambiguous terms like "online", "virtual", "interactive". Use "Internet-based" only if Intervention includes non-web-based Internet components (e.g. email), use "computer-based" or "electronic" only if offline products are used. Use "virtual" only in the context of "virtual reality" (3-D worlds). Use "online" only in the context of "online support groups". Complement or substitute product names with broader terms for the class of products (such as "mobile" or "smart phone" instead of "iphone"), especially if the application runs on different platforms.

subitem not at all important

1 ☐

2 ☐

3 ☐

4 ☐

5 ☐

You're editing your response. Sharing this URL allows others to also edit your response.

FILL OUT A NEW RESPONSE

Does your paper address subitem 1a-i? *

Copy and paste relevant sections from manuscript title (include quotes in quotation marks "like this" to indicate direct quotes from your manuscript), or elaborate on this item by providing additional information not in the ms, or briefly explain why the item is not applicable/relevant for your study

A randomized controlled trial to determine the efficacy of mHealth behavioral change intervention for promoting physical activity in the workplace

1a-ii) Non-web-based components or important co-interventions in title

Mention non-web-based components or important co-interventions in title, if any (e.g., "with telephone support").

subitem not at all important

1 ☐

2 ☐

3 ☐

4 ☐

5 ☐

essential

Does your paper address subitem 1a-ii?

Copy and paste relevant sections from manuscript title (include quotes in quotation marks "like this" to indicate direct quotes from your manuscript), or elaborate on this item by providing additional information not in the ms, or briefly explain why the item is not applicable/relevant for your study

Your answer

You're editing your response. Sharing this URL allows others to also edit your response.

[FILL OUT A NEW RESPONSE](#)

1a-iii) Primary condition or target group in the title

Mention primary condition or target group in the title, if any (e.g., "for children with Type I Diabetes") Example: A Web-based and Mobile Intervention with Telephone Support for Children with Type I Diabetes: Randomized Controlled Trial

subitem not at all important

1 ☐

2 ☐

3 ☐

4 ☐

5 ☐

essential

Does your paper address subitem 1a-iii? *

Copy and paste relevant sections from manuscript title (include quotes in quotation marks "like this" to indicate direct quotes from your manuscript), or elaborate on this item by providing additional information not in the ms, or briefly explain why the item is not applicable/relevant for your study

A randomized controlled trial to determine the efficacy of mHealth behavioral change intervention for promoting physical activity in the workplace

1b) ABSTRACT: Structured summary of trial design, methods, results, and conclusions

NPT extension: Description of experimental treatment, comparator, care providers, centers, and blinding status.

You're editing your response. Sharing this URL allows others to also edit your response.

FILL OUT A NEW RESPONSE

1b-i) Key features/functionalities/components of the intervention and comparator in the METHODS section of the ABSTRACT

Mention key features/functionalities/components of the intervention and comparator in the abstract. If possible, also mention theories and principles used for designing the site. Keep in mind the needs of systematic reviewers and indexers by including important synonyms. (Note: Only report in the abstract what the main paper is reporting. If this information is missing from the main body of text, consider adding it)

subitem not at all important

1 ☐

2 ☐

3 ☐

4 ☐

5 ☐

essential

Does your paper address subitem 1b-i? *

Copy and paste relevant sections from the manuscript abstract (include quotes in quotation marks "like this" to indicate direct quotes from your manuscript), or elaborate on this item by providing additional information not in the ms, or briefly explain why the item is not applicable/relevant for your study

In this parallel, two-arm, randomized controlled trial, healthy adults (n = 327) were randomized to receive a mHealth intervention (tailored text messages combined with self-monitoring (intervention; n = 166) or no intervention (control; n = 161).

You're editing your response. Sharing this URL allows others to also edit your response.

FILL OUT A NEW RESPONSE

1b-ii) Level of human involvement in the METHODS section of the ABSTRACT

Clarify the level of human involvement in the abstract, e.g., use phrases like “fully automated” vs. “therapist/nurse/care provider/physician-assisted” (mention number and expertise of providers involved, if any). (Note: Only report in the abstract what the main paper is reporting. If this information is missing from the main body of text, consider adding it)

subitem not at all important

1 ☐

2 ☐

3 ☐

4 ☐

5 ☐

essential

Does your paper address subitem 1b-ii?

Copy and paste relevant sections from the manuscript abstract (include quotes in quotation marks "like this" to indicate direct quotes from your manuscript), or elaborate on this item by providing additional information not in the ms, or briefly explain why the item is not applicable/relevant for your study

To determine the effectiveness of mobile health (mHealth), particularly text messaging, to improve physical activity (PA) and decrease body mass index (BMI) in healthy adults in the workplace.

Outcomes, PA and BMI, were assessed at baseline and 3 months later. Results showed significant improvement in PA levels (weekly step counts) among the intervention group (difference 1097, 95% CI 922 to 1272, $p < .001$).

You're editing your response. Sharing this URL allows others to also edit your response.

FILL OUT A NEW RESPONSE

1b-iii) Open vs. closed, web-based (self-assessment) vs. face-to-face assessments in the METHODS section of the ABSTRACT

Mention how participants were recruited (online vs. offline), e.g., from an open access website or from a clinic or a closed online user group (closed usergroup trial), and clarify if this was a purely web-based trial, or there were face-to-face components (as part of the intervention or for assessment). Clearly say if outcomes were self-assessed through questionnaires (as common in web-based trials). Note: In traditional offline trials, an open trial (open-label trial) is a type of clinical trial in which both the researchers and participants know which treatment is being administered. To avoid confusion, use "blinded" or "unblinded" to indicated the level of blinding instead of "open", as "open" in web-based trials usually refers to "open access" (i.e. participants can self-enrol). (Note: Only report in the abstract what the main paper is reporting. If this information is missing from the main body of text, consider adding it)

subitem not at all important

1 ☐

2 ☐

3 ☐

4 ☐

5 ☐

essential

Does your paper address subitem 1b-iii?

Copy and paste relevant sections from the manuscript abstract (include quotes in quotation marks "like this" to indicate direct quotes from your manuscript), or elaborate on this item by providing additional information not in the ms, or briefly explain why the item is not applicable/relevant for your study

Your answer

You're editing your response. Sharing this URL allows others to also edit your response.

FILL OUT A NEW RESPONSE

1b-iv) RESULTS section in abstract must contain use data

Report number of participants enrolled/assessed in each group, the use/uptake of the intervention (e.g., attrition/adherence metrics, use over time, number of logins etc.), in addition to primary/secondary outcomes. (Note: Only report in the abstract what the main paper is reporting. If this information is missing from the main body of text, consider adding it)

subitem not at all important

1 ☐

2 ☐

3 ☐

4 ☐

5 ☐

essential

Does your paper address subitem 1b-iv?

Copy and paste relevant sections from the manuscript abstract (include quotes in quotation marks "like this" to indicate direct quotes from your manuscript), or elaborate on this item by providing additional information not in the ms, or briefly explain why the item is not applicable/relevant for your study

Your answer

You're editing your response. Sharing this URL allows others to also edit your response.

FILL OUT A NEW RESPONSE

1b-v) CONCLUSIONS/DISCUSSION in abstract for negative trials

Conclusions/Discussions in abstract for negative trials: Discuss the primary outcome - if the trial is negative (primary outcome not changed), and the intervention was not used, discuss whether negative results are attributable to lack of uptake and discuss reasons. (Note: Only report in the abstract what the main paper is reporting. If this information is missing from the main body of text, consider adding it)

subitem not at all important

1 ☐

2 ☐

3 ☐

4 ☐

5 ☐

essential

Does your paper address subitem 1b-v?

Copy and paste relevant sections from the manuscript abstract (include quotes in quotation marks "like this" to indicate direct quotes from your manuscript), or elaborate on this item by providing additional information not in the ms, or briefly explain why the item is not applicable/relevant for your study

Your answer

INTRODUCTION**2a) In INTRODUCTION: Scientific background and explanation of rationale**

You're editing your response. Sharing this URL allows others to also edit your response.

FILL OUT A NEW RESPONSE

2a-i) Problem and the type of system/solution

Describe the problem and the type of system/solution that is object of the study: intended as stand-alone intervention vs. incorporated in broader health care program? Intended for a particular patient population? Goals of the intervention, e.g., being more cost-effective to other interventions, replace or complement other solutions? (Note: Details about the intervention are provided in "Methods" under 5)

subitem not at all important

1 ☐

2 ☐

3 ☐

4 ☐

5 ☐

essential

You're editing your response. Sharing this URL allows others to also edit your response.

FILL OUT A NEW RESPONSE

Does your paper address subitem 2a-i? *

Copy and paste relevant sections from the manuscript (include quotes in quotation marks "like this" to indicate direct quotes from your manuscript), or elaborate on this item by providing additional information not in the ms, or briefly explain why the item is not applicable/relevant for your study

As a result of economic expansion and technological advancement, more individuals are working in sedentary jobs, [5]. a significant factor in the prevalence of insufficient PA [8]. On average, about 8.5 hours a day are spent working by employees, and with improvements in automation and information technology use, it is anticipated that occupational sedentary time will rise even higher in the future.

Compared to traditional PA interventions, mHealth PA interventions are estimated to be 12% more effective in increasing the level of PA.

mHealth interventions can motivate employees to stay committed to their PA goals in addition to tracking their data and achievements [29,30]. In contrast, some studies found no significant differences between groups of employees in terms of PA level [31,32]. Thus, in this study, we aim to examine the effectiveness of mHealth, specifically text messages combined with self-monitoring, on the level of PA among workers in sedentary jobs.

You're editing your response. Sharing this URL allows others to also edit your response.

FILL OUT A NEW RESPONSE

2a-ii) Scientific background, rationale: What is known about the (type of) system Scientific background, rationale: What is known about the (type of) system that is the object of the study (be sure to discuss the use of similar systems for other conditions/diagnoses, if appropriate), motivation for the study, i.e. what are the reasons for and what is the context for this specific study, from which stakeholder viewpoint is the study performed, potential impact of findings [2]. Briefly justify the choice of the comparator.

subitem not at all important

1 ☐

2 ☐

3 ☐

4 ☐

5 ☐

essential

Does your paper address subitem 2a-ii? *

Copy and paste relevant sections from the manuscript (include quotes in quotation marks "like this" to indicate direct quotes from your manuscript), or elaborate on this item by providing additional information not in the ms, or briefly explain why the item is not applicable/relevant for your study

Mobile health (mHealth) applications have the potential to considerably reduce the prevalence of insufficient PA by overcoming various barriers such as the involved cost; lack of motivation and skills; poorly designed and applied interventions; and fewer tools and resources [14,15]. Compared to traditional PA interventions, mHealth PA interventions are estimated to be 12% more effective in increasing the level of PA [12,13]. In the workplace setting, a systematic review of 25 quasi-experimental and experimental studies observed that 56% of studies demonstrated a significant increase in physical activity [8]. However, other studies reported some limitations related to the type and content of physical activity interventions [16,17].

You're editing your response. Sharing this URL allows others to also edit your response.

FILL OUT A NEW RESPONSE

Does your paper address CONSORT subitem 2b? *

Copy and paste relevant sections from the manuscript (include quotes in quotation marks "like this" to indicate direct quotes from your manuscript), or elaborate on this item by providing additional information not in the ms, or briefly explain why the item is not applicable/relevant for your study

Thus, in this study, we aim to examine the effectiveness of mHealth, specifically text messages combined with self-monitoring, on the level of PA among workers in sedentary jobs.

METHODS

3a) Description of trial design (such as parallel, factorial) including allocation ratio

Does your paper address CONSORT subitem 3a? *

Copy and paste relevant sections from the manuscript (include quotes in quotation marks "like this" to indicate direct quotes from your manuscript), or elaborate on this item by providing additional information not in the ms, or briefly explain why the item is not applicable/relevant for your study

The study design: This study was a randomized controlled trial to investigate the effect of mHealth (text messages and self-monitoring) among employees of a large academic institution in Riyadh, Saudi Arabia, between February and April 2022.

3b) Important changes to methods after trial commencement (such as eligibility criteria), with reasons

You're editing your response. Sharing this URL allows others to also edit your response.

[FILL OUT A NEW RESPONSE](#)

Does your paper address CONSORT subitem 3b? *

Copy and paste relevant sections from the manuscript (include quotes in quotation marks "like this" to indicate direct quotes from your manuscript), or elaborate on this item by providing additional information not in the ms, or briefly explain why the item is not applicable/relevant for your study

There were no Important changes to methods after trial commencement (such as eligibility criteria), with reasons.

3b-i) Bug fixes, Downtimes, Content Changes

Bug fixes, Downtimes, Content Changes: ehealth systems are often dynamic systems. A description of changes to methods therefore also includes important changes made on the intervention or comparator during the trial (e.g., major bug fixes or changes in the functionality or content) (5-iii) and other "unexpected events" that may have influenced study design such as staff changes, system failures/downtimes, etc. [2].

subitem not at all important

1 ☐

2 ☐

3 ☐

4 ☐

5 ☐

essential

Does your paper address subitem 3b-i?

Copy and paste relevant sections from the manuscript (include quotes in quotation marks "like this" to indicate direct quotes from your manuscript), or elaborate on this item by providing additional information not in the ms, or briefly explain why the item is not applicable/relevant for your study

You're editing your response. Sharing this URL allows others to also edit your response.

[FILL OUT A NEW RESPONSE](#)

4a) Eligibility criteria for participants

Does your paper address CONSORT subitem 4a? *

Copy and paste relevant sections from the manuscript (include quotes in quotation marks "like this" to indicate direct quotes from your manuscript), or elaborate on this item by providing additional information not in the ms, or briefly explain why the item is not applicable/relevant for your study

Participants: To be included in the study, participants must be: 1) 18 years of age or older, 2) a full-time employee, 3) in good health, and 4) own a smartphone. We excluded participants who were younger than 18 years old, pregnant, or had any acute disease or mental illness. Eligible participants received a letter to confirm their approval to participate and were informed about the study protocol. The flow chart of the trial is shown in figure 1.

4a-i) Computer / Internet literacy

Computer / Internet literacy is often an implicit "de facto" eligibility criterion - this should be explicitly clarified.

subitem not at all important

1 ☐

2 ☐

3 ☐

4 ☐

5 ☐

essential

You're editing your response. Sharing this URL allows others to also edit your response.

[FILL OUT A NEW RESPONSE](#)

Does your paper address subitem 4a-i?

Copy and paste relevant sections from the manuscript (include quotes in quotation marks "like this" to indicate direct quotes from your manuscript), or elaborate on this item by providing additional information not in the ms, or briefly explain why the item is not applicable/relevant for your study

Your answer

4a-ii) Open vs. closed, web-based vs. face-to-face assessments:

Open vs. closed, web-based vs. face-to-face assessments: Mention how participants were recruited (online vs. offline), e.g., from an open access website or from a clinic, and clarify if this was a purely web-based trial, or there were face-to-face components (as part of the intervention or for assessment), i.e., to what degree got the study team to know the participant. In online-only trials, clarify if participants were quasi-anonymous and whether having multiple identities was possible or whether technical or logistical measures (e.g., cookies, email confirmation, phone calls) were used to detect/prevent these.

subitem not at all important

1 ☐

2 ☐

3 ☐

4 ☐

5 ☐

essential

You're editing your response. Sharing this URL allows others to also edit your response.

FILL OUT A NEW RESPONSE

Does your paper address subitem 4a-ii? *

Copy and paste relevant sections from the manuscript (include quotes in quotation marks "like this" to indicate direct quotes from your manuscript), or elaborate on this item by providing additional information not in the ms, or briefly explain why the item is not applicable/relevant for your study

Data Collection: We obtained the email addresses of all full-time employees (1245 people) at the chosen institution. Then, we randomly selected a preliminary sample of 500, based on the power calculation and accommodating for non-response and attrition rates. After randomly selecting the sample of emails, an electronic invitation was sent to the randomly selected employees to participate in the study. The email contained informed consent, information about the study's background, objectives, procedures, the time required to complete the study, researcher's contact information, privacy and confidentiality confirmations, inclusion criteria, and right to opt-out statement details about the study. Another email was sent as a reminder to ensure a high response rate.

4a-iii) Information giving during recruitment

Information given during recruitment. Specify how participants were briefed for recruitment and in the informed consent procedures (e.g., publish the informed consent documentation as appendix, see also item X26), as this information may have an effect on user self-selection, user expectation and may also bias results.

subitem not at all important

1 ☐

2 ☐

3 ☐

4 ☐

5 ☐

essential

You're editing your response. Sharing this URL allows others to also edit your response.

[FILL OUT A NEW RESPONSE](#)

Does your paper address subitem 4a-iii?

Copy and paste relevant sections from the manuscript (include quotes in quotation marks "like this" to indicate direct quotes from your manuscript), or elaborate on this item by providing additional information not in the ms, or briefly explain why the item is not applicable/relevant for your study

Your answer

4b) Settings and locations where the data were collected

Does your paper address CONSORT subitem 4b? *

Copy and paste relevant sections from the manuscript (include quotes in quotation marks "like this" to indicate direct quotes from your manuscript), or elaborate on this item by providing additional information not in the ms, or briefly explain why the item is not applicable/relevant for your study

This study was a randomized controlled trial to investigate the effect of mHealth (text messages and self-monitoring) among employees of a large academic institution in Riyadh, Saudi Arabia, between February and April 2022.

You're editing your response. Sharing this URL allows others to also edit your response.

FILL OUT A NEW RESPONSE

4b-i) Report if outcomes were (self-)assessed through online questionnaires

Clearly report if outcomes were (self-)assessed through online questionnaires (as common in web-based trials) or otherwise.

subitem not at all important

1 ☐

2 ☐

3 ☐

4 ☐

5 ☐

essential

Does your paper address subitem 4b-i? *

Copy and paste relevant sections from the manuscript (include quotes in quotation marks "like this" to indicate direct quotes from your manuscript), or elaborate on this item by providing additional information not in the ms, or briefly explain why the item is not applicable/relevant for your study

The study's primary outcome was the change in average weekly step count for the whole 3-month study duration between the pre- and post-measurements in each group. The weekly step count was measured by the Google Fit: Activity Tracking TM application, which applies to most smartphones.

You're editing your response. Sharing this URL allows others to also edit your response.

FILL OUT A NEW RESPONSE

4b-ii) Report how institutional affiliations are displayed

Report how institutional affiliations are displayed to potential participants [on ehealth media], as affiliations with prestigious hospitals or universities may affect volunteer rates, use, and reactions with regards to an intervention. (Not a required item – describe only if this may bias results)

subitem not at all important

1 ☐

2 ☐

3 ☐

4 ☐

5 ☐

essential

Does your paper address subitem 4b-ii?

Copy and paste relevant sections from the manuscript (include quotes in quotation marks "like this" to indicate direct quotes from your manuscript), or elaborate on this item by providing additional information not in the ms, or briefly explain why the item is not applicable/relevant for your study

Your answer

5) The interventions for each group with sufficient details to allow replication, including how and when they were actually administered

You're editing your response. Sharing this URL allows others to also edit your response.

FILL OUT A NEW RESPONSE

5-i) Mention names, credential, affiliations of the developers, sponsors, and owners
Mention names, credential, affiliations of the developers, sponsors, and owners [6] (if authors/evaluators are owners or developer of the software, this needs to be declared in a "Conflict of interest" section or mentioned elsewhere in the manuscript).

subitem not at all important

1 ☐

2 ☐

3 ☐

4 ☐

5 ☐

essential

Does your paper address subitem 5-i?

Copy and paste relevant sections from the manuscript (include quotes in quotation marks "like this" to indicate direct quotes from your manuscript), or elaborate on this item by providing additional information not in the ms, or briefly explain why the item is not applicable/relevant for your study

Your answer

You're editing your response. Sharing this URL allows others to also edit your response.

[FILL OUT A NEW RESPONSE](#)

5-ii) Describe the history/development process

Describe the history/development process of the application and previous formative evaluations (e.g., focus groups, usability testing), as these will have an impact on adoption/use rates and help with interpreting results.

subitem not at all important

1 ☐

2 ☐

3 ☐

4 ☐

5 ☐

essential

Does your paper address subitem 5-ii?

Copy and paste relevant sections from the manuscript (include quotes in quotation marks "like this" to indicate direct quotes from your manuscript), or elaborate on this item by providing additional information not in the ms, or briefly explain why the item is not applicable/relevant for your study

Your answer

You're editing your response. Sharing this URL allows others to also edit your response.

FILL OUT A NEW RESPONSE

5-iii) Revisions and updating

Revisions and updating. Clearly mention the date and/or version number of the application/intervention (and comparator, if applicable) evaluated, or describe whether the intervention underwent major changes during the evaluation process, or whether the development and/or content was “frozen” during the trial. Describe dynamic components such as news feeds or changing content which may have an impact on the replicability of the intervention (for unexpected events see item 3b).

subitem not at all important

1 ☐

2 ☐

3 ☐

4 ☐

5 ☐

essential

Does your paper address subitem 5-iii?

Copy and paste relevant sections from the manuscript (include quotes in quotation marks "like this" to indicate direct quotes from your manuscript), or elaborate on this item by providing additional information not in the ms, or briefly explain why the item is not applicable/relevant for your study

Your answer

You're editing your response. Sharing this URL allows others to also edit your response.

FILL OUT A NEW RESPONSE

5-iv) Quality assurance methods

Provide information on quality assurance methods to ensure accuracy and quality of information provided [1], if applicable.

subitem not at all important

1 ☐

2 ☐

3 ☐

4 ☐

5 ☐

essential

Does your paper address subitem 5-iv?

Copy and paste relevant sections from the manuscript (include quotes in quotation marks "like this" to indicate direct quotes from your manuscript), or elaborate on this item by providing additional information not in the ms, or briefly explain why the item is not applicable/relevant for your study

Your answer

You're editing your response. Sharing this URL allows others to also edit your response.

[FILL OUT A NEW RESPONSE](#)

5-v) Ensure replicability by publishing the source code, and/or providing screenshots/screen-capture video, and/or providing flowcharts of the algorithms used

Ensure replicability by publishing the source code, and/or providing screenshots/screen-capture video, and/or providing flowcharts of the algorithms used. Replicability (i.e., other researchers should in principle be able to replicate the study) is a hallmark of scientific reporting.

subitem not at all important

1 ☐

2 ☐

3 ☐

4 ☐

5 ☐

essential

Does your paper address subitem 5-v?

Copy and paste relevant sections from the manuscript (include quotes in quotation marks "like this" to indicate direct quotes from your manuscript), or elaborate on this item by providing additional information not in the ms, or briefly explain why the item is not applicable/relevant for your study

Your answer

You're editing your response. Sharing this URL allows others to also edit your response.

[FILL OUT A NEW RESPONSE](#)

5-vi) Digital preservation

Digital preservation: Provide the URL of the application, but as the intervention is likely to change or disappear over the course of the years; also make sure the intervention is archived (Internet Archive, webcitation.org, and/or publishing the source code or screenshots/videos alongside the article). As pages behind login screens cannot be archived, consider creating demo pages which are accessible without login.

subitem not at all important

1 ☐

2 ☐

3 ☐

4 ☐

5 ☐

essential

Does your paper address subitem 5-vi?

Copy and paste relevant sections from the manuscript (include quotes in quotation marks "like this" to indicate direct quotes from your manuscript), or elaborate on this item by providing additional information not in the ms, or briefly explain why the item is not applicable/relevant for your study

Your answer

You're editing your response. Sharing this URL allows others to also edit your response.

FILL OUT A NEW RESPONSE

5-vii) Access

Access: Describe how participants accessed the application, in what setting/context, if they had to pay (or were paid) or not, whether they had to be a member of specific group. If known, describe how participants obtained "access to the platform and Internet" [1]. To ensure access for editors/reviewers/readers, consider to provide a "backdoor" login account or demo mode for reviewers/readers to explore the application (also important for archiving purposes, see vi).

subitem not at all important

1 ☐

2 ☐

3 ☐

4 ☐

5 ☐

essential

Does your paper address subitem 5-vii? *

Copy and paste relevant sections from the manuscript (include quotes in quotation marks "like this" to indicate direct quotes from your manuscript), or elaborate on this item by providing additional information not in the ms, or briefly explain why the item is not applicable/relevant for your study

Text messages were the primary intervention delivery tool, along with self-monitoring of the weekly step count. The content of the text messages for the intervention group was designed to be concise but effective in promoting PA. The length of each text message averaged 200 characters in length. The content of each message was modified based on weekly feedback from participants and the improvement of weekly steps. The method for designing the modified text messages content over the study period is shown in

You're editing your response. Sharing this URL allows others to also edit your response.

FILL OUT A NEW RESPONSE

5-viii) Mode of delivery, features/functionalities/components of the intervention and comparator, and the theoretical framework

Describe mode of delivery, features/functionalities/components of the intervention and comparator, and the theoretical framework [6] used to design them (instructional strategy [1], behaviour change techniques, persuasive features, etc., see e.g., [7, 8] for terminology). This includes an in-depth description of the content (including where it is coming from and who developed it) [1], "whether [and how] it is tailored to individual circumstances and allows users to track their progress and receive feedback" [6]. This also includes a description of communication delivery channels and – if computer-mediated communication is a component – whether communication was synchronous or asynchronous [6]. It also includes information on presentation strategies [1], including page design principles, average amount of text on pages, presence of hyperlinks to other resources, etc. [1].

subitem not at all important

1 ☐

2 ☐

3 ☐

4 ☐

5 ☐

essential

Does your paper address subitem 5-viii? *

Copy and paste relevant sections from the manuscript (include quotes in quotation marks "like this" to indicate direct quotes from your manuscript), or elaborate on this item by providing additional information not in the ms, or briefly explain why the item is not applicable/relevant for your study

Text messages were the primary intervention delivery tool, along with self-monitoring of the weekly step count. The content of the text messages for the intervention group was designed to be concise but effective in promoting PA. The length of each text message averaged 200 characters in length. The content of each message was modified based on weekly feedback from participants and the improvement of weekly steps. The method

You're editing your response. Sharing this URL allows others to also edit your response.

[FILL OUT A NEW RESPONSE](#)

5-ix) Describe use parameters

Describe use parameters (e.g., intended "doses" and optimal timing for use). Clarify what instructions or recommendations were given to the user, e.g., regarding timing, frequency, heaviness of use, if any, or was the intervention used ad libitum.

subitem not at all important

1 ☐

2 ☐

3 ☐

4 ☐

5 ☐

essential

Does your paper address subitem 5-ix?

Copy and paste relevant sections from the manuscript (include quotes in quotation marks "like this" to indicate direct quotes from your manuscript), or elaborate on this item by providing additional information not in the ms, or briefly explain why the item is not applicable/relevant for your study

Your answer

You're editing your response. Sharing this URL allows others to also edit your response.

FILL OUT A NEW RESPONSE

5-x) Clarify the level of human involvement

Clarify the level of human involvement (care providers or health professionals, also technical assistance) in the e-intervention or as co-intervention (detail number and expertise of professionals involved, if any, as well as "type of assistance offered, the timing and frequency of the support, how it is initiated, and the medium by which the assistance is delivered". It may be necessary to distinguish between the level of human involvement required for the trial, and the level of human involvement required for a routine application outside of a RCT setting (discuss under item 21 – generalizability).

subitem not at all important

1 ☐

2 ☐

3 ☐

4 ☐

5 ☐

essential

Does your paper address subitem 5-x?

Copy and paste relevant sections from the manuscript (include quotes in quotation marks "like this" to indicate direct quotes from your manuscript), or elaborate on this item by providing additional information not in the ms, or briefly explain why the item is not applicable/relevant for your study

Your answer

You're editing your response. Sharing this URL allows others to also edit your response.

FILL OUT A NEW RESPONSE

5-xi) Report any prompts/reminders used

Report any prompts/reminders used: Clarify if there were prompts (letters, emails, phone calls, SMS) to use the application, what triggered them, frequency etc. It may be necessary to distinguish between the level of prompts/reminders required for the trial, and the level of prompts/reminders for a routine application outside of a RCT setting (discuss under item 21 – generalizability).

subitem not at all important

1 ☐

2 ☐

3 ☐

4 ☐

5 ☐

essential

Does your paper address subitem 5-xi? *

Copy and paste relevant sections from the manuscript (include quotes in quotation marks "like this" to indicate direct quotes from your manuscript), or elaborate on this item by providing additional information not in the ms, or briefly explain why the item is not applicable/relevant for your study

The text messages were grounded in behavioral theories, models, and concepts. For instance, the transtheoretical model was utilized to determine the appropriate text message that aligned with the stage of behavior change for the participants. Additionally, major concepts such as self-efficacy, social support, motivation, and locus of control have been employed to improve test-message effectiveness in promoting PA. All prepared text messages were checked for readability and comprehensibility by focus group interviews conducted prior to the initiation of the intervention

You're editing your response. Sharing this URL allows others to also edit your response.

FILL OUT A NEW RESPONSE

5-xii) Describe any co-interventions (incl. training/support)

Describe any co-interventions (incl. training/support): Clearly state any interventions that are provided in addition to the targeted eHealth intervention, as ehealth intervention may not be designed as stand-alone intervention. This includes training sessions and support [1]. It may be necessary to distinguish between the level of training required for the trial, and the level of training for a routine application outside of a RCT setting (discuss under item 21 – generalizability).

subitem not at all important

1 ☐

2 ☐

3 ☐

4 ☐

5 ☐

essential

Does your paper address subitem 5-xii? *

Copy and paste relevant sections from the manuscript (include quotes in quotation marks "like this" to indicate direct quotes from your manuscript), or elaborate on this item by providing additional information not in the ms, or briefly explain why the item is not applicable/relevant for your study

There were no interventions that are provided in addition to the targeted eHealth intervention"

6a) Completely defined pre-specified primary and secondary outcome measures, including how and when they were assessed

You're editing your response. Sharing this URL allows others to also edit your response.

FILL OUT A NEW RESPONSE

Does your paper address CONSORT subitem 6a? *

Copy and paste relevant sections from the manuscript (include quotes in quotation marks "like this" to indicate direct quotes from your manuscript), or elaborate on this item by providing additional information not in the ms, or briefly explain why the item is not applicable/relevant for your study

Outcome measures: The study's primary outcome was the change in average weekly step count for the whole 3-month study duration between the pre- and post-measurements in each group. The weekly step count was measured by the Google Fit: Activity Tracking TM application, which applies to most smartphones. The study's secondary outcome was the difference in the body mass index (BMI), calculated by self-

6a-i) Online questionnaires: describe if they were validated for online use and apply CHERRIES items to describe how the questionnaires were designed/deployed

If outcomes were obtained through online questionnaires, describe if they were validated for online use and apply CHERRIES items to describe how the questionnaires were designed/deployed [9].

subitem not at all important

1 ☐

2 ☐

3 ☐

4 ☐

5 ☐

essential

Does your paper address subitem 6a-i?

Copy and paste relevant sections from manuscript text

Your answer

You're editing your response. Sharing this URL allows others to also edit your response.

FILL OUT A NEW RESPONSE

6a-ii) Describe whether and how “use” (including intensity of use/dosage) was defined/measured/monitored

Describe whether and how “use” (including intensity of use/dosage) was defined/measured/monitored (logins, logfile analysis, etc.). Use/adoption metrics are important process outcomes that should be reported in any ehealth trial.

subitem not at all important

1 ☐

2 ☐

3 ☐

4 ☐

5 ☐

essential

Does your paper address subitem 6a-ii?

Copy and paste relevant sections from manuscript text

Your answer

You're editing your response. Sharing this URL allows others to also edit your response.

FILL OUT A NEW RESPONSE

6a-iii) Describe whether, how, and when qualitative feedback from participants was obtained

Describe whether, how, and when qualitative feedback from participants was obtained (e.g., through emails, feedback forms, interviews, focus groups).

subitem not at all important

1 ☐

2 ☐

3 ☐

4 ☐

5 ☐

essential

Does your paper address subitem 6a-iii?

Copy and paste relevant sections from manuscript text

Your answer

6b) Any changes to trial outcomes after the trial commenced, with reasons

Does your paper address CONSORT subitem 6b? *

Copy and paste relevant sections from the manuscript (include quotes in quotation marks "like this" to indicate direct quotes from your manuscript), or elaborate on this item by providing additional information not in the ms, or briefly explain why the item is not applicable/relevant for your study

There were no changes to trial outcomes

You're editing your response. Sharing this URL allows others to also edit your response.

FILL OUT A NEW RESPONSE

7a) How sample size was determined

NPT: When applicable, details of whether and how the clustering by care provides or centers was addressed

7a-i) Describe whether and how expected attrition was taken into account when calculating the sample size

Describe whether and how expected attrition was taken into account when calculating the sample size.

subitem not at all important

1 ☐

2 ☐

3 ☐

4 ☐

5 ☐

essential

Does your paper address subitem 7a-i?

Copy and paste relevant sections from manuscript title (include quotes in quotation marks "like this" to indicate direct quotes from your manuscript), or elaborate on this item by providing additional information not in the ms, or briefly explain why the item is not applicable/relevant for your study

Your answer

7b) When applicable, explanation of any interim analyses and stopping guidelines

You're editing your response. Sharing this URL allows others to also edit your response.

FILL OUT A NEW RESPONSE

Does your paper address CONSORT subitem 7b? *

Copy and paste relevant sections from the manuscript (include quotes in quotation marks "like this" to indicate direct quotes from your manuscript), or elaborate on this item by providing additional information not in the ms, or briefly explain why the item is not applicable/relevant for your study

There were no interim analyses and stopping guidelines

8a) Method used to generate the random allocation sequence

NPT: When applicable, how care providers were allocated to each trial group

Does your paper address CONSORT subitem 8a? *

Copy and paste relevant sections from the manuscript (include quotes in quotation marks "like this" to indicate direct quotes from your manuscript), or elaborate on this item by providing additional information not in the ms, or briefly explain why the item is not applicable/relevant for your study

After obtaining participant consent and conducting baseline measurements, participants were randomly allocated to groups via computer-generated random numbers in Microsoft Excel for the intervention and control groups with a 1:1 allocation ratio.

8b) Type of randomisation; details of any restriction (such as blocking and block size)

You're editing your response. Sharing this URL allows others to also edit your response.

[FILL OUT A NEW RESPONSE](#)

Does your paper address CONSORT subitem 8b? *

Copy and paste relevant sections from the manuscript (include quotes in quotation marks "like this" to indicate direct quotes from your manuscript), or elaborate on this item by providing additional information not in the ms, or briefly explain why the item is not applicable/relevant for your study

342 people met the inclusion criteria and were eligible to participate in the study. After obtaining participant consent and conducting baseline measurements, participants were randomly allocated to groups via computer-generated random numbers in Microsoft Excel for the intervention and control groups with a 1:1 allocation ratio

9) Mechanism used to implement the random allocation sequence (such as sequentially numbered containers), describing any steps taken to conceal the sequence until interventions were assigned

Does your paper address CONSORT subitem 9? *

Copy and paste relevant sections from the manuscript (include quotes in quotation marks "like this" to indicate direct quotes from your manuscript), or elaborate on this item by providing additional information not in the ms, or briefly explain why the item is not applicable/relevant for your study

342 people met the inclusion criteria and were eligible to participate in the study. After obtaining participant consent and conducting baseline measurements, participants were randomly allocated to groups via computer-generated random numbers in Microsoft Excel for the intervention and control groups with a 1:1 allocation ratio

10) Who generated the random allocation sequence, who enrolled participants, and who assigned participants to interventions

You're editing your response. Sharing this URL allows others to also edit your response.

[FILL OUT A NEW RESPONSE](#)

Does your paper address CONSORT subitem 10? *

Copy and paste relevant sections from the manuscript (include quotes in quotation marks "like this" to indicate direct quotes from your manuscript), or elaborate on this item by providing additional information not in the ms, or briefly explain why the item is not applicable/relevant for your study

342 people met the inclusion criteria and were eligible to participate in the study. After obtaining participant consent and conducting baseline measurements, participants were randomly allocated to groups via computer-generated random numbers in Microsoft Excel for the intervention and control groups with a 1:1 allocation ratio

11a) If done, who was blinded after assignment to interventions (for example, participants, care providers, those assessing outcomes) and how
NPT: Whether or not administering co-interventions were blinded to group assignment

11a-i) Specify who was blinded, and who wasn't

Specify who was blinded, and who wasn't. Usually, in web-based trials it is not possible to blind the participants [1, 3] (this should be clearly acknowledged), but it may be possible to blind outcome assessors, those doing data analysis or those administering co-interventions (if any).

subitem not at all important

1 ☐

2 ☐

3 ☐

4 ☐

5 ☐

essential

You're editing your response. Sharing this URL allows others to also edit your response.

FILL OUT A NEW RESPONSE

Does your paper address subitem 11a-i? *

Copy and paste relevant sections from the manuscript (include quotes in quotation marks "like this" to indicate direct quotes from your manuscript), or elaborate on this item by providing additional information not in the ms, or briefly explain why the item is not applicable/relevant for your study

This is not applicable to our study

11a-ii) Discuss e.g., whether participants knew which intervention was the "intervention of interest" and which one was the "comparator"

Informed consent procedures (4a-ii) can create biases and certain expectations - discuss e.g., whether participants knew which intervention was the "intervention of interest" and which one was the "comparator".

subitem not at all important

1 ☐

2 ☐

3 ☐

4 ☐

5 ☐

essential

Does your paper address subitem 11a-ii?

Copy and paste relevant sections from the manuscript (include quotes in quotation marks "like this" to indicate direct quotes from your manuscript), or elaborate on this item by providing additional information not in the ms, or briefly explain why the item is not applicable/relevant for your study

Your answer

You're editing your response. Sharing this URL allows others to also edit your response.

[FILL OUT A NEW RESPONSE](#)

11b) If relevant, description of the similarity of interventions

(this item is usually not relevant for ehealth trials as it refers to similarity of a placebo or sham intervention to a active medication/intervention)

Does your paper address CONSORT subitem 11b? *

Copy and paste relevant sections from the manuscript (include quotes in quotation marks "like this" to indicate direct quotes from your manuscript), or elaborate on this item by providing additional information not in the ms, or briefly explain why the item is not applicable/relevant for your study

This is not applicable to our study

12a) Statistical methods used to compare groups for primary and secondary outcomes

NPT: When applicable, details of whether and how the clustering by care providers or centers was addressed

Does your paper address CONSORT subitem 12a? *

Copy and paste relevant sections from the manuscript (include quotes in quotation marks "like this" to indicate direct quotes from your manuscript), or elaborate on this item by providing additional information not in the ms, or briefly explain why the item is not applicable/relevant for your study

To estimate the intervention effects between the two groups, we followed the intention-to-treat analysis. No observations were lost due to missing data; however, 15 participants requested to drop out of the study. The intervention and control group dropouts were 5 and 10 participants, respectively. In the initial stage of the analysis, we obtained the descriptive and frequency statistics, means, proportions, and standard deviations of all variables for the intervention and control groups. We used t-tests or chi-square tests, as appropriate, to compare the characteristics of the two groups. After checking for normality, both the primary and secondary outcomes were normally distributed. To estimate the change in the primary and secondary outcomes between the two groups, we performed a linear regression analysis. To account for the occurrence of the regression to the mean, we adjusted for the baseline value of the outcome. Data analyses were performed with SAS version 9.4 (SAS

You're editing your response. Sharing this URL allows others to also edit your response.

FILL OUT A NEW RESPONSE

12a-i) Imputation techniques to deal with attrition / missing values

Imputation techniques to deal with attrition / missing values: Not all participants will use the intervention/comparator as intended and attrition is typically high in ehealth trials. Specify how participants who did not use the application or dropped out from the trial were treated in the statistical analysis (a complete case analysis is strongly discouraged, and simple imputation techniques such as LOCF may also be problematic [4]).

subitem not at all important

1 ☐

2 ☐

3 ☐

4 ☐

5 ☐

essential

Does your paper address subitem 12a-i? *

Copy and paste relevant sections from the manuscript (include quotes in quotation marks "like this" to indicate direct quotes from your manuscript), or elaborate on this item by providing additional information not in the ms, or briefly explain why the item is not applicable/relevant for your study

There were no attrition or missing value

12b) Methods for additional analyses, such as subgroup analyses and adjusted analyses

You're editing your response. Sharing this URL allows others to also edit your response.

[FILL OUT A NEW RESPONSE](#)

Does your paper address CONSORT subitem 12b? *

Copy and paste relevant sections from the manuscript (include quotes in quotation marks "like this" to indicate direct quotes from your manuscript), or elaborate on this item by providing additional information not in the ms, or briefly explain why the item is not applicable/relevant for your study

To estimate the intervention effects between the two groups, we followed the intention-to-treat analysis. No observations were lost due to missing data; however, 15 participants requested to drop out of the study. The intervention and control group dropouts were 5 and 10 participants, respectively. In the initial stage of the analysis, we obtained the descriptive and frequency statistics, means, proportions, and standard deviations of all variables for the intervention and control groups. We used t-tests or chi-square tests, as appropriate, to compare the characteristics of the two groups. After checking for normality, both the primary and secondary outcomes were normally distributed. To estimate the change in the primary and secondary outcomes between the two groups, we performed a linear regression analysis. To account for the occurrence of the regression to the mean, we adjusted for the baseline value of the outcome. Data analyses were performed with SAS version 9.4 (SAS Institute, Cary, NC, USA). P values less than .05 were considered statistically significant for all tests.

X26) REB/IRB Approval and Ethical Considerations [recommended as subheading under "Methods"] (not a CONSORT item)

X26-i) Comment on ethics committee approval

subitem not at all important

1 ☐

2 ☐

3 ☐

4 ☐

5 ☐

You're editing your response. Sharing this URL allows others to also edit your response.

FILL OUT A NEW RESPONSE

Does your paper address subitem X26-i?

Copy and paste relevant sections from the manuscript (include quotes in quotation marks "like this" to indicate direct quotes from your manuscript), or elaborate on this item by providing additional information not in the ms, or briefly explain why the item is not applicable/relevant for your study

Your answer

x26-ii) Outline informed consent procedures

Outline informed consent procedures e.g., if consent was obtained offline or online (how? Checkbox, etc.?), and what information was provided (see 4a-ii). See [6] for some items to be included in informed consent documents.

subitem not at all important

1 ☐

2 ☐

3 ☐

4 ☐

5 ☐

essential

Does your paper address subitem X26-ii?

Copy and paste relevant sections from the manuscript (include quotes in quotation marks "like this" to indicate direct quotes from your manuscript), or elaborate on this item by providing additional information not in the ms, or briefly explain why the item is not applicable/relevant for your study

Your answer

You're editing your response. Sharing this URL allows others to also edit your response.

[FILL OUT A NEW RESPONSE](#)

X26-iii) Safety and security procedures

Safety and security procedures, incl. privacy considerations, and any steps taken to reduce the likelihood or detection of harm (e.g., education and training, availability of a hotline)

subitem not at all important

1 ☐

2 ☐

3 ☐

4 ☐

5 ☐

essential

Does your paper address subitem X26-iii?

Copy and paste relevant sections from the manuscript (include quotes in quotation marks "like this" to indicate direct quotes from your manuscript), or elaborate on this item by providing additional information not in the ms, or briefly explain why the item is not applicable/relevant for your study

Your answer

RESULTS

13a) For each group, the numbers of participants who were randomly assigned, received intended treatment, and were analysed for the primary outcome
NPT: The number of care providers or centers performing the intervention in each group and the number of patients treated by each care provider in each center

You're editing your response. Sharing this URL allows others to also edit your response.

FILL OUT A NEW RESPONSE

Does your paper address CONSORT subitem 13a? *

Copy and paste relevant sections from the manuscript (include quotes in quotation marks "like this" to indicate direct quotes from your manuscript), or elaborate on this item by providing additional information not in the ms, or briefly explain why the item is not applicable/relevant for your study

342 participants were enrolled and randomly allocated to the intervention or control study (1:1 allocation ratio). A total of 327 participants completed the baseline and 3-month follow-up measurements. Table 1 presents baseline participant characteristics for the intervention and control groups. In the first month of the study, 15 participants notified the authors of their voluntary withdrawal from the study. At the follow-up measurement, the number of participants in the intervention and the control group was 166 and 161, respectively. No significant differences were found between the two

13b) For each group, losses and exclusions after randomisation, together with reasons

Does your paper address CONSORT subitem 13b? (NOTE: Preferably, this is shown in a CONSORT flow diagram) *

Copy and paste relevant sections from the manuscript (include quotes in quotation marks "like this" to indicate direct quotes from your manuscript), or elaborate on this item by providing additional information not in the ms, or briefly explain why the item is not applicable/relevant for your study

342 participants were enrolled and randomly allocated to the intervention or control study (1:1 allocation ratio). A total of 327 participants completed the baseline and 3-month follow-up measurements. Table 1 presents baseline participant characteristics for the intervention and control groups. In the first month of the study, 15 participants notified the authors of their voluntary withdrawal from the study. At the follow-up measurement, the number of participants in the intervention and the control group was 166 and 161, respectively. No significant differences were found between the two

You're editing your response. Sharing this URL allows others to also edit your response.

FILL OUT A NEW RESPONSE

13b-i) Attrition diagram

Strongly recommended: An attrition diagram (e.g., proportion of participants still logging in or using the intervention/comparator in each group plotted over time, similar to a survival curve) or other figures or tables demonstrating usage/dose/engagement.

subitem not at all important

1 ☐

2 ☐

3 ☐

4 ☐

5 ☐

essential

Does your paper address subitem 13b-i?

Copy and paste relevant sections from the manuscript or cite the figure number if applicable (include quotes in quotation marks "like this" to indicate direct quotes from your manuscript), or elaborate on this item by providing additional information not in the ms, or briefly explain why the item is not applicable/relevant for your study

Your answer

14a) Dates defining the periods of recruitment and follow-up

You're editing your response. Sharing this URL allows others to also edit your response.

[FILL OUT A NEW RESPONSE](#)

Does your paper address CONSORT subitem 14a? *

Copy and paste relevant sections from the manuscript (include quotes in quotation marks "like this" to indicate direct quotes from your manuscript), or elaborate on this item by providing additional information not in the ms, or briefly explain why the item is not applicable/relevant for your study

342 participants were enrolled and randomly allocated to the intervention or control study (1:1 allocation ratio). A total of 327 participants completed the baseline and 3-month follow-up measurements. Table 1 presents baseline participant characteristics for the intervention and control groups. In the first month of the study, 15 participants notified the authors of their voluntary withdrawal from the study. At the follow-up measurement, the number of participants in the intervention and the control group was 166 and 161, respectively. No significant differences were found between the two

14a-i) Indicate if critical "secular events" fell into the study period

Indicate if critical "secular events" fell into the study period, e.g., significant changes in Internet resources available or "changes in computer hardware or Internet delivery resources"

subitem not at all important

1 ☐

2 ☐

3 ☐

4 ☐

5 ☐

essential

You're editing your response. Sharing this URL allows others to also edit your response.

FILL OUT A NEW RESPONSE

Does your paper address subitem 14a-i?

Copy and paste relevant sections from the manuscript (include quotes in quotation marks "like this" to indicate direct quotes from your manuscript), or elaborate on this item by providing additional information not in the ms, or briefly explain why the item is not applicable/relevant for your study

Your answer

14b) Why the trial ended or was stopped (early)

Does your paper address CONSORT subitem 14b? *

Copy and paste relevant sections from the manuscript (include quotes in quotation marks "like this" to indicate direct quotes from your manuscript), or elaborate on this item by providing additional information not in the ms, or briefly explain why the item is not applicable/relevant for your study

This is not applicable to our study.

15) A table showing baseline demographic and clinical characteristics for each group

NPT: When applicable, a description of care providers (case volume, qualification, expertise, etc.) and centers (volume) in each group

You're editing your response. Sharing this URL allows others to also edit your response.

FILL OUT A NEW RESPONSE

Does your paper address CONSORT subitem 15? *

Copy and paste relevant sections from the manuscript (include quotes in quotation marks "like this" to indicate direct quotes from your manuscript), or elaborate on this item by providing additional information not in the ms, or briefly explain why the item is not applicable/relevant for your study

Table1. Baseline participant characteristics (n = 166)

Variable	Control (n=161)	Intervention (n=166)	P value
Gender	0.82		
Male	69 (42.9)	69 (41.6)	
Female	92 (57.1)	97 (58.4)	
Age, n (%)	0.13		
18-24	45 (28)	55 (33.1)	
25-34	107 (66.5)	108 (65.1)	
≥ 35	9 (5.6)	3 (1.8)	
Marital status, n (%)	0.91		
Married	59 (36.6)	60 (36.1)	
Single	97 (63.3)	101 (63.9)	
Education, n (%)	0.95		
Bachelor or below	151 (93.8)	156 (94)	
Masters or above	10 (6.2)	10 (6)	
Weight, mean (SD)	69.32 (12.31)	69.14 (11.95)	0.89
Height, mean (SD)	164.20 (8.48)	164.07 (8.41)	0.87
BMI, mean (SD)	25.68 (3.85)	25.67 (3.86)	0.98
Physical activity, mean (SD)	3851.61 (2574.18)	3888.37 (2531.23)	0.91

You're editing your response. Sharing this URL allows others to also edit your response.

FILL OUT A NEW RESPONSE

15-i) Report demographics associated with digital divide issues

In ehealth trials it is particularly important to report demographics associated with digital divide issues, such as age, education, gender, social-economic status, computer/Internet/ehealth literacy of the participants, if known.

subitem not at all important

1 ☐

2 ☐

3 ☐

4 ☐

5 ☐

essential

You're editing your response. Sharing this URL allows others to also edit your response.

FILL OUT A NEW RESPONSE

Does your paper address subitem 15-i? *

Copy and paste relevant sections from the manuscript (include quotes in quotation marks "like this" to indicate direct quotes from your manuscript), or elaborate on this item by providing additional information not in the ms, or briefly explain why the item is not applicable/relevant for your study

Table1. Baseline participant characteristics (n = 166)

Variable	Control (n=161)	Intervention (n=166)	P value
Gender	0.82		
Male	69 (42.9)	69 (41.6)	
Female	92 (57.1)	97 (58.4)	
Age, n (%)	0.13		
18-24	45 (28)	55 (33.1)	
25-34	107 (66.5)	108 (65.1)	
≥ 35	9 (5.6)	3 (1.8)	
Marital status, n (%)	0.91		
Married	59 (36.6)	60 (36.1)	
Single	97 (63.3)	101 (63.9)	
Education, n (%)	0.95		
Bachelor or below	151 (93.8)	156 (94)	
Masters or above	10 (6.2)	10 (6)	
Weight, mean (SD)	69.32 (12.31)	69.14 (11.95)	0.89
Height, mean (SD)	164.20 (8.48)	164.07 (8.41)	0.87
BMI, mean (SD)	25.68 (3.85)	25.67 (3.86)	0.98
Physical activity, mean (SD)	3851.61 (2574.18)	3888.37 (2531.23)	0.91

16) For each group, number of participants (denominator) included in each analysis and whether the analysis was by original assigned groups

You're editing your response. Sharing this URL allows others to also edit your response.

FILL OUT A NEW RESPONSE

16-i) Report multiple “denominators” and provide definitions

Report multiple “denominators” and provide definitions: Report N’s (and effect sizes) “across a range of study participation [and use] thresholds” [1], e.g., N exposed, N consented, N used more than x times, N used more than y weeks, N participants “used” the intervention/comparator at specific pre-defined time points of interest (in absolute and relative numbers per group). Always clearly define “use” of the intervention.

subitem not at all important

1 ☐

2 ☐

3 ☐

4 ☐

5 ☐

essential

Does your paper address subitem 16-i? *

Copy and paste relevant sections from the manuscript (include quotes in quotation marks "like this" to indicate direct quotes from your manuscript), or elaborate on this item by providing additional information not in the ms, or briefly explain why the item is not applicable/relevant for your study

This is not applicable to our study

You're editing your response. Sharing this URL allows others to also edit your response.

FILL OUT A NEW RESPONSE

16-ii) Primary analysis should be intent-to-treat

Primary analysis should be intent-to-treat, secondary analyses could include comparing only "users", with the appropriate caveats that this is no longer a randomized sample (see 18-i).

subitem not at all important

1 ☐

2 ☐

3 ☐

4 ☐

5 ☐

essential

Does your paper address subitem 16-ii?

Copy and paste relevant sections from the manuscript (include quotes in quotation marks "like this" to indicate direct quotes from your manuscript), or elaborate on this item by providing additional information not in the ms, or briefly explain why the item is not applicable/relevant for your study

Your answer

17a) For each primary and secondary outcome, results for each group, and the estimated effect size and its precision (such as 95% confidence interval)

You're editing your response. Sharing this URL allows others to also edit your response.

FILL OUT A NEW RESPONSE

Does your paper address CONSORT subitem 17a? *

Copy and paste relevant sections from the manuscript (include quotes in quotation marks "like this" to indicate direct quotes from your manuscript), or elaborate on this item by providing additional information not in the ms, or briefly explain why the item is not applicable/relevant for your study

Outcomes and estimations

Over the 3-month follow-up period, the averages of the weekly step counts for the intervention group and control group were 4984 steps (SD = 2483) and 3853 steps (SD = 2590), respectively. No significant within-group differences were detected by age or sex. In the intervention group, participants significantly increased their step count ($p < .001$). In the control group, there were no significant changes in pre- and post-intervention step count. Table 2 presents the means and standard deviations for PA and BMI for the intervention and control groups. Simple linear regression was used to test if the change in step count was significant between the groups after adjusting for the baseline measure of step count. The overall regression model was statistically significant ($F = 81.15$, $p < .001$). The model estimated that the intervention group had a significant increase of 1097 related to the control group ($B = 1097$, 95% CI 922 to 1272, $p < .001$) with a large effect size ($d = 1.34$; CI = 1.10, 1.58).

For the secondary outcome, BMI, the between-groups difference was minimal but significant in average BMI ($p < .001$). In the 3-month follow-up measurements, the intervention group's average BMI (25.10, SD = 3.81) decreased significantly relative to the average BMI of the control group (25.7, SD = 3.84). We used simple linear regression to test the significance of the difference between the groups after adjusting for the baseline measure of BMI. Overall, the regression was significant ($F = 72.37$, $p = .001$). According to the model, the intervention group had a significant decrease of 0.60 compared to the control group ($B = 0.60$, 95% CI .50 to .69, $p = .001$).

You're editing your response. Sharing this URL allows others to also edit your response.

[FILL OUT A NEW RESPONSE](#)

17a-i) Presentation of process outcomes such as metrics of use and intensity of use

In addition to primary/secondary (clinical) outcomes, the presentation of process outcomes such as metrics of use and intensity of use (dose, exposure) and their operational definitions is critical. This does not only refer to metrics of attrition (13-b) (often a binary variable), but also to more continuous exposure metrics such as "average session length". These must be accompanied by a technical description how a metric like a "session" is defined (e.g., timeout after idle time) [1] (report under item 6a).

subitem not at all important

1 ☐

2 ☐

3 ☐

4 ☐

5 ☐

essential

Does your paper address subitem 17a-i?

Copy and paste relevant sections from the manuscript (include quotes in quotation marks "like this" to indicate direct quotes from your manuscript), or elaborate on this item by providing additional information not in the ms, or briefly explain why the item is not applicable/relevant for your study

Your answer

17b) For binary outcomes, presentation of both absolute and relative effect sizes is recommended

You're editing your response. Sharing this URL allows others to also edit your response.

[FILL OUT A NEW RESPONSE](#)

Does your paper address CONSORT subitem 17b? *

Copy and paste relevant sections from the manuscript (include quotes in quotation marks "like this" to indicate direct quotes from your manuscript), or elaborate on this item by providing additional information not in the ms, or briefly explain why the item is not applicable/relevant for your study

This not applicable to our study

18) Results of any other analyses performed, including subgroup analyses and adjusted analyses, distinguishing pre-specified from exploratory

Does your paper address CONSORT subitem 18? *

Copy and paste relevant sections from the manuscript (include quotes in quotation marks "like this" to indicate direct quotes from your manuscript), or elaborate on this item by providing additional information not in the ms, or briefly explain why the item is not applicable/relevant for your study

This not applicable to our study

You're editing your response. Sharing this URL allows others to also edit your response.

FILL OUT A NEW RESPONSE

18-i) Subgroup analysis of comparing only users

A subgroup analysis of comparing only users is not uncommon in ehealth trials, but if done, it must be stressed that this is a self-selected sample and no longer an unbiased sample from a randomized trial (see 16-iii).

subitem not at all important

1 ☐

2 ☐

3 ☐

4 ☐

5 ☐

essential

Does your paper address subitem 18-i?

Copy and paste relevant sections from the manuscript (include quotes in quotation marks "like this" to indicate direct quotes from your manuscript), or elaborate on this item by providing additional information not in the ms, or briefly explain why the item is not applicable/relevant for your study

Your answer

19) All important harms or unintended effects in each group (for specific guidance see CONSORT for harms)

You're editing your response. Sharing this URL allows others to also edit your response.

FILL OUT A NEW RESPONSE

Does your paper address CONSORT subitem 19? *

Copy and paste relevant sections from the manuscript (include quotes in quotation marks "like this" to indicate direct quotes from your manuscript), or elaborate on this item by providing additional information not in the ms, or briefly explain why the item is not applicable/relevant for your study

This not applicable to our study

19-i) Include privacy breaches, technical problems

Include privacy breaches, technical problems. This does not only include physical "harm" to participants, but also incidents such as perceived or real privacy breaches [1], technical problems, and other unexpected/unintended incidents. "Unintended effects" also includes unintended positive effects [2].

subitem not at all important

1 ☐

2 ☐

3 ☐

4 ☐

5 ☐

essential

Does your paper address subitem 19-i?

Copy and paste relevant sections from the manuscript (include quotes in quotation marks "like this" to indicate direct quotes from your manuscript), or elaborate on this item by providing additional information not in the ms, or briefly explain why the item is not applicable/relevant for your study

Your answer

You're editing your response. Sharing this URL allows others to also edit your response.

[FILL OUT A NEW RESPONSE](#)

19-ii) Include qualitative feedback from participants or observations from staff/researchers

Include qualitative feedback from participants or observations from staff/researchers, if available, on strengths and shortcomings of the application, especially if they point to unintended/unexpected effects or uses. This includes (if available) reasons for why people did or did not use the application as intended by the developers.

subitem not at all important

1 ☐

2 ☐

3 ☐

4 ☐

5 ☐

essential

Does your paper address subitem 19-ii?

Copy and paste relevant sections from the manuscript (include quotes in quotation marks "like this" to indicate direct quotes from your manuscript), or elaborate on this item by providing additional information not in the ms, or briefly explain why the item is not applicable/relevant for your study

Your answer

DISCUSSION

22) Interpretation consistent with results, balancing benefits and harms, and considering other relevant evidence

NPT: In addition, take into account the choice of the comparator, lack of or partial blinding,

You're editing your response. Sharing this URL allows others to also edit your response.

[FILL OUT A NEW RESPONSE](#)

22-i) Restate study questions and summarize the answers suggested by the data, starting with primary outcomes and process outcomes (use)

Restate study questions and summarize the answers suggested by the data, starting with primary outcomes and process outcomes (use).

subitem not at all important

1 ☐

2 ☐

3 ☐

4 ☐

5 ☐

essential

You're editing your response. Sharing this URL allows others to also edit your response.

FILL OUT A NEW RESPONSE

Does your paper address subitem 22-i? *

Copy and paste relevant sections from the manuscript (include quotes in quotation marks "like this" to indicate direct quotes from your manuscript), or elaborate on this item by providing additional information not in the ms, or briefly explain why the item is not applicable/relevant for your study

MHealth and its applications have shown increasing promise in enhancing and maintaining PA levels among the public [33,34]. However, the extent of PA improvements due to mHealth interventions varied substantially depending on the type of intervention or the studied population. To our knowledge, this is the first RCT to examine the effectiveness of tailored text messages combined with self-monitoring in improving PA for healthy adults in the workplace. In our study, we examined the effectiveness of mHealth among adults known to have mostly sedentary computer-based jobs in an academic institution. Our mHealth intervention incorporated several features. First, we used automated randomization to maintain the concealed allocation of participants between the groups and ensure a balance of baseline factors. Second, rather than relying on self-reported measurements of PA, we objectively measured weekly physical activity by recording weekly step counts using the smartphone application. Third, participants received two text messages every day for the whole period of the intervention to effectively maintain engagement levels. Fourth, sent text messages were tailored by experts in the field based on weekly participant feedback. Fifth, we combined text messages with self-monitoring every week to examine their collective effect on PA. Overall, our findings demonstrated a significant difference in both primary (PA) and secondary (BMI) outcomes, which will help inform future interventions and programs.

22-ii) Highlight unanswered new questions, suggest future research

Highlight unanswered new questions, suggest future research.

subitem not at all important

1 ☐

2 ☐

3 ☐

4 ☐

5 ☐

You're editing your response. Sharing this URL allows others to also edit your response.

[FILL OUT A NEW RESPONSE](#)

Does your paper address subitem 22-ii?

Copy and paste relevant sections from the manuscript (include quotes in quotation marks "like this" to indicate direct quotes from your manuscript), or elaborate on this item by providing additional information not in the ms, or briefly explain why the item is not applicable/relevant for your study

Your answer

20) Trial limitations, addressing sources of potential bias, imprecision, and, if relevant, multiplicity of analyses

20-i) Typical limitations in ehealth trials

Typical limitations in ehealth trials: Participants in ehealth trials are rarely blinded. Ehealth trials often look at a multiplicity of outcomes, increasing risk for a Type I error. Discuss biases due to non-use of the intervention/usability issues, biases through informed consent procedures, unexpected events.

subitem not at all important

1 ☐

2 ☐

3 ☐

4 ☐

5 ☐

essential

You're editing your response. Sharing this URL allows others to also edit your response.

FILL OUT A NEW RESPONSE

Does your paper address subitem 20-i? *

Copy and paste relevant sections from the manuscript (include quotes in quotation marks "like this" to indicate direct quotes from your manuscript), or elaborate on this item by providing additional information not in the ms, or briefly explain why the item is not applicable/relevant for your study

MHealth and its applications have shown increasing promise in enhancing and maintaining PA levels among the public [33,34]. However, the extent of PA improvements due to mHealth interventions varied substantially depending on the type of intervention or the studied population. To our knowledge, this is the first RCT to examine the effectiveness of tailored text messages combined with self-monitoring in improving PA for healthy adults in the workplace. In our study, we examined the effectiveness of mHealth among adults known to have mostly sedentary computer-based jobs in an academic institution. Our mHealth intervention incorporated several features. First, we used automated randomization to maintain the concealed allocation of participants between the groups and ensure a balance of baseline factors. Second, rather than relying on self-reported measurements of PA, we objectively measured weekly physical activity by recording weekly step counts using the smartphone application. Third, participants received two text messages every day for the whole period of the intervention to effectively maintain engagement levels. Fourth, sent text messages were tailored by experts in the field based on weekly participant feedback. Fifth, we combined text messages with self-monitoring every week to examine their collective effect on PA. Overall, our findings demonstrated a significant difference in both primary (PA) and secondary (BMI) outcomes, which will help inform future interventions and programs.

21) Generalisability (external validity, applicability) of the trial findings

NPT: External validity of the trial findings according to the intervention, comparators, patients, and care providers or centers involved in the trial

You're editing your response. Sharing this URL allows others to also edit your response.

FILL OUT A NEW RESPONSE

21-i) Generalizability to other populations

Generalizability to other populations: In particular, discuss generalizability to a general Internet population, outside of a RCT setting, and general patient population, including applicability of the study results for other organizations

subitem not at all important

1 ☐

2 ☐

3 ☐

4 ☐

5 ☐

essential

Does your paper address subitem 21-i?

Copy and paste relevant sections from the manuscript (include quotes in quotation marks "like this" to indicate direct quotes from your manuscript), or elaborate on this item by providing additional information not in the ms, or briefly explain why the item is not applicable/relevant for your study

Your answer

You're editing your response. Sharing this URL allows others to also edit your response.

FILL OUT A NEW RESPONSE

21-ii) Discuss if there were elements in the RCT that would be different in a routine application setting

Discuss if there were elements in the RCT that would be different in a routine application setting (e.g., prompts/reminders, more human involvement, training sessions or other co-interventions) and what impact the omission of these elements could have on use, adoption, or outcomes if the intervention is applied outside of a RCT setting.

subitem not at all important

1 ☐

2 ☐

3 ☐

4 ☐

5 ☐

essential

Does your paper address subitem 21-ii?

Copy and paste relevant sections from the manuscript (include quotes in quotation marks "like this" to indicate direct quotes from your manuscript), or elaborate on this item by providing additional information not in the ms, or briefly explain why the item is not applicable/relevant for your study

Your answer

OTHER INFORMATION

23) Registration number and name of trial registry

You're editing your response. Sharing this URL allows others to also edit your response.

[FILL OUT A NEW RESPONSE](#)

Does your paper address CONSORT subitem 23? *

Copy and paste relevant sections from the manuscript (include quotes in quotation marks "like this" to indicate direct quotes from your manuscript), or elaborate on this item by providing additional information not in the ms, or briefly explain why the item is not applicable/relevant for your study

Trial No: APP/2022/040, Sri Lanka Clinical Trials Registry Committee

24) Where the full trial protocol can be accessed, if available

Does your paper address CONSORT subitem 24? *

Cite a Multimedia Appendix, other reference, or copy and paste relevant sections from the manuscript (include quotes in quotation marks "like this" to indicate direct quotes from your manuscript), or elaborate on this item by providing additional information not in the ms, or briefly explain why the item is not applicable/relevant for your study

This not applicable to our study

25) Sources of funding and other support (such as supply of drugs), role of funders

Does your paper address CONSORT subitem 25? *

Copy and paste relevant sections from the manuscript (include quotes in quotation marks "like this" to indicate direct quotes from your manuscript), or elaborate on this item by providing additional information not in the ms, or briefly explain why the item is not applicable/relevant for your study

The authors extend their appreciation to the Deputyship for Research & Innovation, Ministry of Education in Saudi Arabia for funding this research work through project number 7932

You're editing your response. Sharing this URL allows others to also edit your response.

FILL OUT A NEW RESPONSE

X27-i) State the relation of the study team towards the system being evaluated

In addition to the usual declaration of interests (financial or otherwise), also state the relation of the study team towards the system being evaluated, i.e., state if the authors/evaluators are distinct from or identical with the developers/sponsors of the intervention.

subitem not at all important

1 ☐

2 ☐

3 ☐

4 ☐

5 ☐

essential

Does your paper address subitem X27-i?

Copy and paste relevant sections from the manuscript (include quotes in quotation marks "like this" to indicate direct quotes from your manuscript), or elaborate on this item by providing additional information not in the ms, or briefly explain why the item is not applicable/relevant for your study

Your answer

About the CONSORT EHEALTH checklist

You're editing your response. Sharing this URL allows others to also edit your response.

[FILL OUT A NEW RESPONSE](#)

As a result of using this checklist, did you make changes in your manuscript? *

- ☐ yes, major changes
- ☒ yes, minor changes
- ☐ no

What were the most important changes you made as a result of using this checklist?

Your answer

How much time did you spend on going through the checklist INCLUDING making * changes in your manuscript

3 days going through the checklist INCLUDING making changes in your manuscript

As a result of using this checklist, do you think your manuscript has improved? *

- ☒ yes
- ☐ no
- ☐ Other:

You're editing your response. Sharing this URL allows others to also edit your response.

FILL OUT A NEW RESPONSE

Would you like to become involved in the CONSORT EHEALTH group?

This would involve for example becoming involved in participating in a workshop and writing an "Explanation and Elaboration" document

☐ yes

☐ no

☐ Other:

Any other comments or questions on CONSORT EHEALTH

Your answer

STOP - Save this form as PDF before you click submit

To generate a record that you filled in this form, we recommend to generate a PDF of this page (on a Mac, simply select "print" and then select "print as PDF") before you submit it.

When you submit your (revised) paper to JMIR, please upload the PDF as supplementary file.

Don't worry if some text in the textboxes is cut off, as we still have the complete information in our database. Thank you!

Final step: Click submit !

Click submit so we have your answers in our database!

Submit

Never submit passwords through Google Forms.

This content is neither created nor endorsed by Google. [Report Abuse](#) - [Terms of Service](#) - [Privacy Policy](#).

You're editing your response. Sharing this URL allows others to also edit your response.

FILL OUT A NEW RESPONSE

You're editing your response. Sharing this URL allows others to also edit your response.

FILL OUT A NEW RESPONSE